Sonnet biotherapeutics announces abstract accepted for presentation in a poster session at the aacr 2022 annual meeting

Princeton, nj / accesswire / february 9, 2022 / sonnet biotherapeutics holdings, inc. (nasdaq:sonn) ("sonnet" or the "company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that data from preclinical studies of the company's proprietary fully human albumin binding candidates, son-1010, son-1210, and son-1410, will be presented at the upcoming american association for cancer research (aacr) annual meeting 2022, to be held april 8-13, in new orleans, louisiana. details of the abstract and poster presentation are as follows: title: an innovative human platform for targeted delivery of bispecific interleukins to tumors abstract number: 4229 session: immunology presentation type: poster session date and time: wednesday april 13, 2022; 9:00 am - 12:30 pm edt location: new orleans convention center, exhibit halls d-h, poster section 38 poster board number: 9 about sonnet biotherapeutics holdings, inc. sonnet biotherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bispecific action.
SONN Ratings Summary
SONN Quant Ranking